- /
- Supported exchanges
- / US
- / LIMN.NASDAQ
Liminatus Pharma, Inc. Class A Common Stock (LIMN NASDAQ) stock market data APIs
Liminatus Pharma, Inc. Class A Common Stock Financial Data Overview
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Liminatus Pharma, Inc. Class A Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Liminatus Pharma, Inc. Class A Common Stock data using free add-ons & libraries
Get Liminatus Pharma, Inc. Class A Common Stock Fundamental Data
Liminatus Pharma, Inc. Class A Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -4 063 116
- Earnings Per Share: -22
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Liminatus Pharma, Inc. Class A Common Stock Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: NaN
Get Liminatus Pharma, Inc. Class A Common Stock End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Liminatus Pharma, Inc. Class A Common Stock News
New
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Liminatus Pharma Inc. FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company") today announced that its board of directors has adopted...
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Liminatus Pharma Inc. FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biopharmaceutical company developing novel therapies...
Liminatus Pharma Amends Merger Agreement With InnocsAI To Expand Oncology Pipeline
(RTTNews) - Liminatus Pharma, Inc. (LIMN), a biotechnology company developing cancer therapies, announced it has amended and restated its definitive merger agreement with InnocsAI LLC, an oncology bio...
Liminatus Pharma secures $1.9M cash via warrant exercises
Liminatus Pharma (LIMN [https://seekingalpha.com/symbol/LIMN]) has entered into a warrant exercise agreement to exercise certain outstanding warrants to purchase an aggregate of 10.34M shares of commo...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.